Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36

Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset

Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date1

Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases

EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the presentation of updated data from the Phase 1 portion of COMPARE, a Phase 1/2 investigator-initiated trial (IIT) evaluating miv-cel (mivocabtagene autoleucel, KYV-101) in patients with active anti-citrullinated protein antibody (ACPA)-positive, treatment-refractory rheumatoid arthritis (RA). The data will be presented today in an oral presentation by Charité - University of Berlin at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London.

Building on the safety and efficacy results reported at ACR Convergence 2025, the updated data showed a single dose of miv-cel resulted in deep B-cell depletion with subsequent reconstitution with a naïve B-cell phenotype in ACPA-positive RA patients. These findings demonstrate the potential of an immune reset and translate into meaningful clinical improvement.